UOB and FPT sign MoU to advance AI, technology transformation and financial innovation opportunities

SINGAPORE, June 1, 2026 /PRNewswire/ — UOB and global technology corporation FPT have…

Calibrite Display Plus HL Receives Apple Approval for Hardware-Level Display Calibration

For the first time, creative professionals can calibrate Apple displays at hardware…

BofA Securities Asia Forum Gathers Global Investors Amid Surge in Hedge Funds Allocations

Key points BofA Securities hosted its fourth annual Asia Alternatives Forum, bringing…

ASCO 2026 | CStone Presents Updated Clinical Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody), Reinforcing Triple-Target Synergy and Delivering Strong Proof-of-Concept

First-line NSCLC – Compelling Activity Across All PD-L1 SubgroupsIn first-line non-small cell…

Long-term Follow-up Results of CARsgen's Satri-cel as Sequential Therapy After First-Line Treatment for Gastric Cancer Presented at the 2026 ASCO Annual Meeting

SHANGHAI, June 1, 2026 /PRNewswire/ — CARsgen Therapeutics Holdings Limited (Stock Code:…

MICROIP to Debut "AI Vehicle System Business Group" and Edge AI Innovations at COMPUTEX 2026

TAIPEI, June 1, 2026 /PRNewswire/ — MICROIP (TPEx: 7796), specializing in AI…

Jyong Biotech CEO Outlines FDA Pathway and Global Strategy in PharmaBoardroom Live Interview

TAIPEI, June 1, 2026 /PRNewswire/ — Jyong Biotech Ltd. (Nasdaq: MENS) (the…

D3 Bio Presents First-Line Data for Elisrasib (D3S-001) at ASCO 2026; Next-Generation KRAS G12C Inhibitor Shows Landmark Efficacy in Untreated NSCLC

Elisrasib monotherapy delivers an ORR of 78.0% and median PFS of 12.4…